Active surveillance protocol in prostate cancer in Portugal

被引:1
|
作者
Gaspar, S. R. da Silva [1 ]
Fernandes, M. [1 ]
Castro, A. [1 ]
Oliveira, T. [1 ]
Dias, J. Santos [1 ]
dos Reis, J. Palma [1 ]
机构
[1] Ctr Hosp Univ Lisboa Norte, Hosp Santa Maria, Dept Urol, Lisbon, Portugal
来源
ACTAS UROLOGICAS ESPANOLAS | 2022年 / 46卷 / 06期
关键词
Active surveillance; Prostate cancer; Watchful waiting; Portugal; MRI; Biopsy; VERSION; 2; MEN; COMPLICATIONS; MANAGEMENT; BIOPSIES;
D O I
10.1016/j.acuro.2021.01.010
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: To examine clinical practice patterns in locally managing patients under an active surveillance protocol among Portuguese urologists. Introduction: Prostate cancer (PCa) is a heterogeneous disease with many prostate adeno-carcinomas being indolent and a low probability of ever causing symptoms or death. Active surveillance (AS) is a form of conservative management aimed to reduce over-treatment for low-risk PCa patients. Over the years, experience with AS has grown considerably and is now standard in some countries, however a universal protocol still does not exist. Methods: Nationwide anonymous e-survey concerning habits and practices on AS among Portu-guese urologists, that consisted of 12 questions and was sent electronically to all 368 current members of the Portuguese Urological Association. Results: 56 urologists were surveyed (15.21% answer rate), evenly distributed geographically and allocated according to years of experience as well as number of PCa patients managed monthly. The vast majority of respondents recommends AS to their patients, particularly ISUP grade 1 patients, whose PSA serum level is bellow 20ng/mL. Observance of AS programs by patients was not in question but concerns exist over psychological morbidity while harboring disease. Majority believed that international guidelines surveillance protocols were adequate and sufficient, but there are some constraints concerning availability of periodic MRIs and re -biopsy needs. Conclusions: AS seems to be sustained in urologist clinical practice, although patients still lag to adhere and choose for active treatment. AS may not be an easy choice for patients and clinicians due to uncertainty of disease progression, risk of loss to follow-up and repeated biopsies but is also a cause for anxiety, depression, uncertainty and a perception of danger. (c) 2021 AEU. Published by Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:329 / 339
页数:11
相关论文
共 50 条
  • [31] Medium-term Outcomes of Active Surveillance for Localised Prostate Cancer
    Selvadurai, Elizabeth D.
    Singhera, Mausam
    Thomas, Karen
    Mohammed, Kabir
    Woode-Amissah, Ruth
    Horwich, Alan
    Huddart, Robert A.
    Dearnaley, David P.
    Parker, Chris C.
    EUROPEAN UROLOGY, 2013, 64 (06) : 981 - 987
  • [32] Guy's and St Thomas NHS Foundation active surveillance prostate cancer cohort: a characterisation of a prostate cancer active surveillance database
    Shah, Salonee
    Beckmann, Kerri
    Van Hemelrijck, Mieke
    Challacombe, Ben
    Popert, Rick
    Dasgupta, Prokar
    Rusere, Jonah
    Zisengwe, Grace
    Elhage, Oussama
    Santaolalla, Aida
    BMC CANCER, 2021, 21 (01)
  • [33] Active Surveillance for Prostate Cancer: A Systematic Review of the Literature
    Dall'Era, Marc A.
    Albertsen, Peter C.
    Bangma, Christopher
    Carroll, Peter R.
    Carter, H. Ballentine
    Cooperberg, Matthew R.
    Freedland, Stephen J.
    Klotz, Laurence H.
    Parker, Christopher
    Soloway, Mark S.
    EUROPEAN UROLOGY, 2012, 62 (06) : 976 - 983
  • [34] Active surveillance in intermediate risk prostate cancer: is it safe?
    Krishnananthan, Nishanth
    Lawrentschuk, Nathan
    INTERNATIONAL BRAZ J UROL, 2016, 42 (03): : 418 - 421
  • [35] Optimization of follow up in prostate cancer active surveillance
    Celma Domenech, Ana
    Planos Morin, Jacques
    Morote Robles, Juan
    ARCHIVOS ESPANOLES DE UROLOGIA, 2014, 67 (05): : 442 - 451
  • [36] Quality of life in active surveillance for early prostate cancer
    Kato, Takuma
    Sugimoto, Mikio
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 (04) : 296 - 306
  • [37] Active surveillance for low-risk prostate cancer
    Herlemann, Annika
    Stief, Christian G.
    UROLOGE, 2016, 55 (02): : 269 - 278
  • [38] Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study
    van den Bergh, Roderick C. N.
    Vasarainen, Hanna
    van der Poel, Henk G.
    Vis-Maters, Jenneke J.
    Rietbergen, John B.
    Pickles, Tom
    Cornel, Erik B.
    Valdagni, Riccardo
    Jaspars, Joris J.
    van der Hoeven, John
    Staerman, Frederic
    Oomens, Eric H. G. M.
    Rannikko, Antti
    Roemeling, Stijn
    Steyerberg, Ewout W.
    Roobol, Monique J.
    Schroder, Fritz H.
    Bangma, Chris H.
    BJU INTERNATIONAL, 2010, 105 (07) : 956 - 962
  • [39] Active Surveillance for Low-risk Prostate Cancer
    Mazzucchelli, Roberta
    Nesseris, Ioannis
    Cheng, Liang
    Lopez-Beltran, Antonio
    Montironi, Rodolfo
    Scarpelli, Marina
    ANTICANCER RESEARCH, 2010, 30 (09) : 3683 - 3692
  • [40] Active surveillance for low-risk prostate cancer
    Bangma, Chris H.
    Bul, Meelan
    van der Kwast, Theo H.
    Pickles, Tom
    Korfage, Ida J.
    Hoeks, Caroline M.
    Steyerberg, Ewout W.
    Jenster, Guido
    Kattan, Michael W.
    Bellardita, Lara
    Carroll, Peter R.
    Denis, Louis J.
    Parker, Chris
    Roobol, Monique J.
    Emberton, Mark
    Klotz, Laurence H.
    Rannikko, Antti
    Kakehi, Yoshiyuki
    Lane, Janet A.
    Schroder, Fritz H.
    Semjonow, Axel
    Trock, Bruce J.
    Valdagni, Riccardo
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2013, 85 (03) : 295 - 302